Cancer PTEN Loss - Multi Purpose Inhibitor, page-10

This is from a broker from their website dated 2 Dec 2020

"We have increased our valuation to US$184m or US$14.55 per ADR from US$104m or US$10.98 per ADR. This is driven by increasing our probability of success for paxalisib in GBM to 35% from 20%."

There you have it - in one sentence, I believe as to the embedded issues with the SP.


The broker did not place this information on the Kazia Therapeutics website.....the company (CEO) did. The information is not correct and does not need to be in place - as its the company who has discretion to put the info up, on the website or take it down. The fact - this info is in place - underlines deep issues which highlights inexperience in this area.



-------------

I have done more than my share in dealings with the company in this regard. Indeed no surprise to me, if my name is on the dartboard in the company lunchroom.

I would call on shareholders to do something - you know what you have to do. Stand up for yourselves.

In particular one poster has alot of strength and capacity to do something...that person harvett I would ask to talk to the company and help make some chances. Shareholders deserve it and it is up to people like harvett to act. Thanks.